Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®
NCT02722122
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Interventions
DRUG:
AIR DNase™
Sponsor
Protalix